Veeva Systems Inc. $VEEV Stock Sold by Ninety One UK Ltd

Key Points

• Ninety One UK Ltd cut its Veeva Systems stake by 26.3% in the third quarter, selling 17,268 shares and retaining 48,346 shares valued at approximately $13.8 million. Institutional investors collectively own 88.2% of the company.
• Veeva insiders sold 51,591 shares worth about $13.4 million over the past 90 days, including sales by a director and an executive vice president; one sale was made to cover tax obligations tied to vested equity awards.
• Despite the selling, Veeva reported quarterly earnings and revenue above analyst expectations, with revenue up 17.6% year over year. Analysts maintain a “Moderate Buy” consensus and an average price target of $285.92, while the stock’s elevated valuation and potentially slowing R&D growth remain risks.

Ninety One UK Ltd lowered its stake in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) by 26.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,346 shares of the technology company's stock after selling 17,268 shares during the quarter. Ninety One UK Ltd's holdings in Veeva Systems were worth $13,800,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Formuepleje A S purchased a new stake in shares of Veeva Systems in the third quarter valued at about $458,000. Turtle Creek Wealth Advisors LLC purchased a new position in Veeva Systems during the third quarter worth about $271,000. Mainsail Asset Management LLC purchased a new position in Veeva Systems during the third quarter worth about $266,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its holdings in Veeva Systems by 1.2% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,664 shares of the technology company's stock worth $1,331,000 after purchasing an additional 57 shares during the last quarter. Finally, Fortitude Family Office LLC grew its position in Veeva Systems by 2,178.6% in the 3rd quarter. Fortitude Family Office LLC now owns 319 shares of the technology company's stock worth $91,000 after purchasing an additional 305 shares in the last quarter. Institutional investors own 88.20% of the company's stock.

Insiders Place Their Bets

In other Veeva Systems news, Director Priscilla Hung sold 750 shares of the business's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total value of $195,780.00. Following the transaction, the director directly owned 3,242 shares in the company, valued at $846,291.68. The trade was a 18.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Rizzo sold 4,841 shares of the business's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $276.51, for a total transaction of $1,338,584.91. Following the completion of the transaction, the executive vice president owned 7,665 shares in the company, valued at approximately $2,119,449.15. The trade was a 38.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 51,591 shares of company stock valued at $13,355,945. Company insiders own 10.60% of the company's stock.

Veeva Systems Price Performance

Shares of Veeva Systems stock opened at $313.01 on Friday. The firm has a market cap of $50.68 billion, a PE ratio of 51.48, a P/E/G ratio of 1.27 and a beta of 0.93. Veeva Systems Inc. has a 1 year low of $148.05 and a 1 year high of $315.02. The stock has a fifty day moving average price of $268.19 and a 200-day moving average price of $207.22.

Veeva Systems (NYSE:VEEV - Get Free Report) last issued its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, topping analysts' consensus estimates of $2.23 by $0.12. The company had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The firm's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, equities analysts anticipate that Veeva Systems Inc. will post 6.70 EPS for the current fiscal year.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Expanded IQVIA partnership strengthens Veeva’s clinical-software position. IQVIA selected Veeva’s Clinical Trial Management System, eTMF, Study Startup, and Site Connect applications as enterprise standards across its global clinical studies. The agreement expands Veeva’s footprint with a major contract research organization and could support broader adoption among biopharma customers. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
• Positive Sentiment: Analyst support remains favorable. Oppenheimer maintained a $325 price target, and average brokerage recommendations remain optimistic. While analyst ratings can be biased, the continued positive stance is supporting investor confidence. Oppenheimer Keeps USD 325 Target for Veeva Systems Stock
• Positive Sentiment: Technical momentum attracted additional buying. Veeva moved above a buy point in an early-stage chart pattern, with reports describing increased institutional or “big money” exposure to the AI and life-sciences software theme. Veeva Stock Breaks Out as Big Money Grabs Exposure
• Positive Sentiment: Veeva’s growth platform continues to broaden. More than 175 emerging biotechs reportedly use Veeva Basics, adding to the company’s clinical, regulatory, and quality software ecosystem. Veeva also plans to hold a virtual investor day on November 5, which could provide additional detail on strategy and growth opportunities. Veeva to Host Virtual Investor Day
• Neutral Sentiment: Veeva is receiving elevated investor attention, and industry forecasts point to long-term expansion in life-sciences IT driven by cloud and artificial-intelligence adoption. These factors support the broader investment narrative but do not represent new company-specific revenue.
• Negative Sentiment: Oppenheimer noted that Veeva’s guidance may imply further deceleration in research-and-development growth. This could temper expectations and remains a risk for a stock trading at a premium valuation. Veeva Systems’ Research and Development Growth Tracking to Plan

Analyst Upgrades and Downgrades

Several equities research analysts have commented on VEEV shares. Stifel Nicolaus set a $300.00 price objective on shares of Veeva Systems in a research note on Thursday, August 27th. Barclays lifted their target price on shares of Veeva Systems from $275.00 to $315.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. UBS Group boosted their target price on Veeva Systems from $190.00 to $290.00 and gave the stock a "neutral" rating in a research note on Thursday, August 27th. Guggenheim upped their target price on Veeva Systems from $276.00 to $310.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $295.00 target price on shares of Veeva Systems in a report on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $285.92.

About Veeva Systems

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company's product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.

Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.